Orgenesis Secures An Additional $5 Million Investment From Metalmark Capital To Accelerate Growth Of Point-Of-Care Service Subsidiary

Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a global biotech company working to unlock the full potential of cell and gene therapies (CGT) at the point of care, and Metalmark Capital Partners (“Metalmark”), a leading private equity firm with extensive expertise in the healthcare sector, today announced that Metalmark has agreed to make an additional growth investment of $5 million into Orgenesis’ US-based point-of-care (POCare) services subsidiary, Morgenesis LLC (“Morgenesis”). This investment follows the previously announced investment of $30 million in November 2022. In addition, Metalmark has committed to investing up to an additional $15 million, subject to the achievement of certain milestones.